Otsuka Holdings Co (JP:4578) has released an update.
Otsuka Holdings Co., Ltd. has announced the approval of an additional indication for its drug Rexulti in Japan, for treating agitation associated with Alzheimer’s disease. The approval follows successful phase 3 trials showing significant improvement in agitation symptoms, with the drug being well tolerated among patients. This marks the third indication for Rexulti in Japan, which is part of Otsuka’s commitment to addressing the needs of an aging population and providing comprehensive care options.
For further insights into JP:4578 stock, check out TipRanks’ Stock Analysis page.
